N/A
Completed N=24
everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
Chronic Kidney Diseases
Source: ClinicalTrials.gov NCT03708562 ↗
Enrolled (actual)
24
Serious AEs
16.7%
Results posted
Jan 2020
Primary outcomePrimary: Number of Participants With Procedural Success — 19 Participants
Summary
Prospective, single-center study to evaluate the everlinQ endoAVF System when used to create an endoAVF in hemodialysis patients. This study aims to investigate expansion of the percutaneous venous access location to the superficial system which may provide additional procedural benefit.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Procedural Success |
19 | — |
| PRIMARY Adverse Event Rate |
4 | — |
| SECONDARY Percentage of Participants With Primary Patency at 6 Months Post Index Procedure |
70.8 | — |
| SECONDARY Number of Participants With EndoAVF Maturation at 1, 3, and 6 Months Post Index Procedure |
19; 20; 20 | — |
| SECONDARY Time to Cannulation (Months) |
1.2 | — |
| SECONDARY Number of Participants With Cannulation Success at Defined Follow-up Intervals |
0; 11; 13; 13 | — |
| SECONDARY Percentage of Participants With Assisted Primary Patency at 6 Months |
70.8 | — |
| SECONDARY Percentage of Participants With Secondary Patency at 6 Months Post Index Procedure |
70.8 | — |
| SECONDARY Percentage of Participants With Functional Patency of the endoAVF at 6 Months Post Index Procedure |
90.9 | — |
| SECONDARY Number of Participants With EndoAVF Related Reintervention |
3 | — |
| SECONDARY Percentage of Participants With Modified Primary Patency at 6 Months Post Index Procedure |
70.8 | — |
Eligibility Criteria
Inclusion Criteria
- Eligible for a native arteriovenous fistula.
- Adult (age >18 years old).
- Established, non-reversible kidney failure requiring hemodialysis (including pre-dialysis patients).
- Target vein diameter(s) at fistula site ≥ 2.0 mm.
- Target artery diameter at fistula site ≥ 2.0 mm.
- Procedural access site artery and vein diameter ≥ 2.0 mm.
- At least one superficial outflow vein diameter ≥ 2.5 mm and in communication with the perforating vein.
- Estimated life expectancy > 1 year.
- Patient is free of clinically significant conditions or illness within 30 days prior to the AV fistula that may compromise the procedure.
- Presence of an antecubital perforating vein diameter ≥ 2.0 mm.
Exclusion Criteria
- Known central venous stenosis or central vein narrowing > 50% based on imaging on the same side as the planned AVF creation.
- Upper extremity venous occlusion(s) and/or vessel abnormality(ies) on the same side as the planned AVF creation that precludes endovascular AVF creation by the everlinQ System as deemed by the interventionalists' clinical judgment.
- Prior surgically created access in the planned treatment location.
- Functioning surgical access in the planned treatment arm.
- Pregnant women.
- New York Heart Association (NYHA) class III or IV heart failure.
- Hypercoagulable state.
- Known bleeding diathesis.
- Immunosuppression, defined as use of immunosuppressive medications used to treat an active condition.
- Documented history of drug abuse including intravenous drugs within six months of AVF creation.
- "Planned" concomitant major surgical procedure within 6 months of enrollment or previous major surgery within 30 days of enrollment.
- Currently being treated with another investigational device or drug.
- Known allergy to contrast dye which cannot be adequately pre-medicated.
- Known adverse effects to sedation and/or anesthesia which cannot be adequately pre- medicated.
- Patients who do not have an ulnar or radial artery.
- Distance between target artery and vein or other anatomical abnormality will not permit catheters to be introduced, navigated to fistula site, or allow magnets to align vessels sufficiently to create the fistula.
- Evidence of calcification in vessels at the fistula site.
- Evidence of active infections on the day of the index procedure.
- Written informed consent not obtained.
Data sourced from ClinicalTrials.gov (NCT03708562). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.